Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InflaRx NVIFRX +5.83%34 3-Year EBITDA Growth Rate is -4.40% as of Jun. 2026. GuruFocus rates IFRX with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,130 Biotechnology companies, InflaRx NV ranks worse than 74.34% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was -4.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 11.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -5.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of InflaRx NV was 32.50% per year. The lowest was -96.20% per year. And the median was 8.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
InflaRx NV 3-Year EBITDA Growth Rate Related Terms
IFRX vs VRXA, TTRX, IRD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, InflaRx NV's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InflaRx NV 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InflaRx NV's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where InflaRx NV's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -4.40% mean?
InflaRx NV (IFRX) has a 3-Year EBITDA Growth Rate of -4.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for InflaRx NV and its competitors. According to the industry distribution chart, InflaRx NV ranks #840 out of 1130 companies in the Biotechnology industry, placing it in the top 74.3%.
Is InflaRx NV's 3-Year EBITDA Growth Rate too high?
InflaRx NV's current 3-Year EBITDA Growth Rate is -4.40%. Based on the distribution chart, InflaRx NV ranks #840 out of 1130 companies in the Biotechnology industry, which is below the industry midpoint. Overall, InflaRx NV has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does InflaRx NV's 3-Year EBITDA Growth Rate compare to VRXA and TTRX?
According to the Biotechnology industry distribution chart, InflaRx NV ranks #840 out of 1130 companies for 3-Year EBITDA Growth Rate. This places InflaRx NV in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for InflaRx NV and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InflaRx NV's current 3-Year EBITDA Growth Rate is -4.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InflaRx NV stock overvalued right now?
InflaRx NV (IFRX) has a current 3-Year EBITDA Growth Rate of -4.40%. The current 3-Year EBITDA Growth Rate is -4.40%. InflaRx NV's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For InflaRx NV (IFRX), the current 3-Year EBITDA Growth Rate is -4.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
34GF Score
Get the complete analysis for IFRX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IFRX has been successfully added to your 
